Collegium Pharmaceutical (COLL) Total Debt (2014 - 2026)

Collegium Pharmaceutical has reported Total Debt for 13 years, with the latest figure at $852.8 million in Q2 2026.

• On a quarterly basis, Total Debt rose 45.72% year-over-year to $852.8 million in Q2 2026; TTM through Jun 2026 was $852.8 million, a 45.72% increase from a year earlier, with the FY2025 full-year figure at $571.1 million, down 7.18% from the prior year.
• Total Debt was $852.8 million for Q2 2026 at Collegium Pharmaceutical, up from $564.3 million in the prior quarter.
• The five-year high for Total Debt was $852.8 million in Q2 2026, with the low at $316.2 million in Q2 2024.
• Average Total Debt over 5 years is $551.6 million, with a median of $570.6 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Debt soared 409.07% in 2022, then tumbled 35.9% in 2024.
• Over 5 years, Total Debt stood at $560.1 million in 2022, then slipped by 27.68% to $405.0 million in 2023, then jumped by 51.91% to $615.3 million in 2024, then fell by 7.18% to $571.1 million in 2025, then soared by 49.33% to $852.8 million in 2026.
• The last three Total Debt figures came in at $852.8 million (Q2 2026), $564.3 million (Q1 2026), and $571.1 million (Q4 2025), per Business Quant data.